Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder.

Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB, Graham AJ, Langberg JM, Kahn RS.

J Am Acad Child Adolesc Psychiatry. 2011 Nov;50(11):1129-1139.e2. doi: 10.1016/j.jaac.2011.08.002. Epub 2011 Sep 15.

2.

Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder.

Kim BN, Kim JW, Hong SB, Cho SC, Shin MS, Yoo HJ.

Behav Brain Funct. 2010 Oct 7;6:57. doi: 10.1186/1744-9081-6-57.

3.

Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.

Froehlich TE, McGough JJ, Stein MA.

CNS Drugs. 2010 Feb;24(2):99-117. doi: 10.2165/11530290-000000000-00000. Review.

4.

A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder.

McGough JJ, McCracken JT, Loo SK, Manganiello M, Leung MC, Tietjens JR, Trinh T, Baweja S, Suddath R, Smalley SL, Hellemann G, Sugar CA.

J Am Acad Child Adolesc Psychiatry. 2009 Dec;48(12):1155-64. doi: 10.1097/CHI.0b013e3181bc72e3.

5.

The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents.

Polanczyk G, Faraone SV, Bau CH, Victor MM, Becker K, Pelz R, Buitelaar JK, Franke B, Kooij S, van der Meulen E, Cheon KA, Mick E, Purper-Ouakil D, Gorwood P, Stein MA, Cook EH Jr, Rohde LA.

Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1419-24. doi: 10.1002/ajmg.b.30855.

6.

The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy.

Stein MA, McGough JJ.

Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):475-90, xi-xii. doi: 10.1016/j.chc.2007.11.009. Review.

Supplemental Content

Support Center